# Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

> **NCT04982575** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 92 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide 2.4 mg
- **DRUG:** Cagrilintide 2.4 mg
- **DRUG:** Placebo (semaglutide)
- **DRUG:** Placebo (cagrilintide)

## Key facts

- **NCT ID:** NCT04982575
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-02
- **Primary completion:** 2022-07-07
- **Final completion:** 2022-07-07
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982575, "Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04982575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*